Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

SBC Medical Group Holdings (SBC) EBITDA (2023 - 2025)

SBC Medical Group Holdings (SBC) has disclosed EBITDA for 3 consecutive years, with $6.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA fell 74.22% year-over-year to $6.0 million, compared with a TTM value of $36.6 million through Sep 2025, down 60.66%, and an annual FY2024 reading of $30.0 million, up 12.65% over the prior year.
  • EBITDA was $6.0 million for Q3 2025 at SBC Medical Group Holdings, down from $10.9 million in the prior quarter.
  • Across five years, EBITDA topped out at $51.5 million in Q4 2023 and bottomed at -$11.7 million in Q4 2024.
  • Average EBITDA over 3 years is $12.4 million, with a median of $8.6 million recorded in 2024.
  • Peak annual rise in EBITDA hit 2302.71% in 2024, while the deepest fall reached 122.66% in 2024.
  • Year by year, EBITDA stood at $51.5 million in 2023, then crashed by 122.66% to -$11.7 million in 2024, then soared by 151.76% to $6.0 million in 2025.
  • Business Quant data shows EBITDA for SBC at $6.0 million in Q3 2025, $10.9 million in Q2 2025, and $31.3 million in Q1 2025.